PHADER Registry now open to clinics

December 2014

PHAryngeal electrical stimulation for treatment of neurogenic Dysphagia: a European Registry (PHADER).

This observational, prospective, post-market follow-up clinical study is designed to enable Phagenesis to demonstrate the real world clinical outcome of Pharyngeal Electrical Stimulation (PES) for the treatment of dysphagia resulting from different neurogenic disorders.

If you are a healthcare professional interested in being part of PHADER please contact us.

For further information see CIP Synopsis PHADER.

From Apprentice to Administration and Finance Officer in just one year

August 2014

MANCHESTER apprentice Johnathon Kynaston has been appointed to administration and finance officer of city based company Phagenesis just one year after starting work at the company.

The 17-year-old has secured this new permanent position following a successful apprenticeship placement by national training provider Positive Outcomes, which specialises in work-based training and apprenticeships. Johnathon is now responsible for a range of areas within the company, handling both office and clinical sectors of the business.

Positive Outcomes training advisor Melissa Cribben worked with Johnathon throughout his training.

She said: “With changes in the age of school leavers, I can see only further growth for apprenticeships. Johnathon is a great example of how beneficial apprentices can be to employers and to those taking them.

“I gave Johnathon the confidence to complete the work and supported him throughout, all the rest he did himself.”

Talking about his time with Phagenesis, Johnathon said he enjoyed working for the company.

He said: “I joined the company nearly a year ago now, but it does not feel like a year at all – I’ve learnt lots of new things and thoroughly enjoyed it in the process. I’m just thrilled that I am now a fully-fledged member of the team, and I cannot wait to continue progressing in my career with Phagenesis.

The apprenticeship was a fantastic opportunity and one that I have benefited greatly from. My advice to others is to seriously consider an apprenticeship – they’re extremely useful as you can learn just as much as you could at college yet you’re gaining work-experience and applying the skills learnt within a work environment.

Johnathon’s trainee officer at Phagenesis Caroline Clayton, who started out as an apprentice herself,  worked alongside Johnathon every step of the way – she said: “Johnathon joined Phagenesis straight from school with very little work experience and immediately took on a number of specific responsibilities such as IT, office and clinical administration. He immediately became a highly valued member of the team and we have all been impressed by his development over the past year. I would wholeheartedly recommend Positive Outcomes and the apprenticeship programme. I personally think that apprenticeships are a great way into the working world.”

Positive Outcomes’ chief executive officer, Chris Longmate, added: “Johnathon is a brilliant example of what can be achieved once enrolled onto a Positive Outcomes apprenticeship. We are all very proud of his success and can’t wait to see how he develops on from here. Apprenticeships are working and Johnathon proves that.”

Johnathon started his apprenticeship just two weeks after completing his GSCE’s at the Droylsden Academy. His progression and training highlight the impact which apprenticeship schemes are having in Manchester and across the country.

Dysphagic patients needed for swallowing treatment

September 2013

Swallowing food and drink is part of our daily life and something that we do automatically. Sometimes people who suffer from brain injury (such as stroke) or neurodegenerative disease (such as Parkinson’s Disease) may have difficulties with swallowing which compromises their health.

One of the complications of a poor swallow is that food and drink may go down the wrong way and end up in the lungs, where it can cause chest infections. Swallowing problems termed ‘Dysphagia’ affect thousands of people every year. In fact, someone you know may have swallowing problems.

We are currently recruiting people with dysphagia for clinical studies assessing the effects of a swallowing treatment that uses electrical pharyngeal stimulation. Studies will involve visits to a clinical research facility for the electrical stimulation treatment and assessments of swallowing function.

If you are interested and would like further information regarding studies, please feel free to contact us using the details below:

Tel: 0161 820 9569

Email: chronic@phagenesis.com

Remuneration for your travel expenses and subsistence will be available.

This study has been approved by the MHRA and an NREC.

Update: The recruitment has finished.

 

Dr. Oern Stuge appointed Chairman of Phagenesis

May 2013

Manchester, UK – 21 March 2013 − Phagenesis®, the world’s leading company in the treatment of dysphagia, has appointed Dr. Oern Stuge, former senior executive at Medtronic and Abbott Laboratories, as Chairman.

The appointment comes as Phagenesis® secures its first revenues from its Phagenyx® treatment for dysphagia, launched in Q4 2012. Dysphagia is the inability to swallow safely, a condition caused by a variety of neurological conditions including stroke, Parkinson’s disease, cerebral palsy and multiple sclerosis.

Dr. Stuge brings to Phagenesis® his extensive experience at Medtronic Inc. in different positions including Senior Vice President & President Cardiac Surgery, President EMEA, Latin America, Canada & India, member of the Executive Committee & Operating Committee. He began his career as a practicing physician and has an MD from the University of Oslo, and an MBA from IMD in Lausanne.

Dr. Stuge said: “I am honoured to be invited to chair the board of Phagenesis®, whose innovative technology addresses a genuine unmet need. With the company’s technology we hope to help many patients: dysphagia is a debilitating condition that affects tens of millions worldwide who, until now, have not had access to a treatment that addresses the underlying neurological mechanism of the condition.”

Henry Hyde Thomson, outgoing chairman, commented: “In the three years I have served as Chairman, Phagenesis® has grown from a start-up to a revenue-generating company which has successfully launched its dysphagia treatment. Dr. Stuge’s extensive experience in the field of medical devices will help ensure Phagenesis’ continued success as it rolls out this vital treatment to patients and their carers around the world.”

Phagenyx® is the result of almost 20 years of R&D at the University of Manchester, UK. Treatment consists of a calibrated electrical signal delivered to the oropharynx (back of the throat) for 10 minutes a day for three consecutive days. Randomised controlled trials have shown that patients improve their swallowing function, and brain imaging shows that this is achieved through cortical remapping; a healthy part of the brain takes over the function of the damaged swallowing control centre.

Daniel Green, CEO, said: “Dr. Stuge’s appointment to the chairmanship is a great vote of confidence in Phagenesis® and the prospects for the Phagenyx® treatment, as we focus on the delivery of proven tools to help clinicians improve the lives of dysphagic patients in their care.”

Phagenesis expands Series B Financing to $17 million

May 2013

Manchester, UK – 22 May 2013 − Phagenesis, the world’s leading company in the treatment of dysphagia, has expanded its Series B financing to $17m. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital.

The increased resources will be used to launch the Phagenyx® treatment, which received its CE Mark in 2012, in new territories and to expand clinical testing in new patient groups. Dysphagia is the inability to swallow safely, a debilitating condition that affects about half of stroke patients. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Current management of the condition includes tube-feeding patients, which can lead to a significant loss of quality of life.

The Phagenyx® treatment involves an electrical stimulus to the oropharynx (a region of the back of the throat) for 10 minutes a day for three consecutive days. Peer-reviewed, randomised clinical trials have shown that this treatment is safe and effective in improving participants’ safe swallowing ability.

Daniel Green, CEO of Phagenesis, said: “Our investors continue to show confidence in our ability to deliver this new technology to doctors to treat patients who might otherwise face a lifetime of tube feeding.” Oern Stuge, MD, recently appointed Chairman of Phagenesis®, said: “Dysphagia is one of the great unmet medical needs in the treatment of stroke, which healthcare systems around the world recognise as an increasingly important challenge both clinically and economically.”

Ashok Dhanrajgir, Director of Phagenesis® and a partner at Inventages, said: “Inventages remains a committed investor and major participant in the expanded Series B Financing, which will enable Phagenesis® to bring this important new technology to a wider patient population.”